debt_leverage_profile
Near-zero debt; pre-revenue biotech funded primarily by equity raises; a 20% rate rise has minimal direct debt-service impact
Inferred
Agent_Inference
interest_rate_sensitivity
Low direct sensitivity; higher rates increase equity dilution cost and reduce biotech investor appetite, pressuring future fundraising rounds
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) Israeli biosynthesis inputs dependent on regional geopolitical stability; 2) specialty botanical raw material sourcing concentration in limited global suppliers
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; primary market is Israel/North America; sovereign currency devaluation risk is low but ILS/USD fluctuation is a factor
Inferred
Agent_Inference
geographic_footprint
Operations concentrated in Israel; revenue emerging in North America; ILS depreciation vs USD provides cost advantage but limits local reinvestment
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Proprietary BioFarm technology is self-developed; however, bioreactor hardware suppliers may represent concentrated single-source dependency above 30%
Inferred
Agent_Inference
business_model_type_primary
B2B ingredient supplier / licensing model; cloud dependency is minimal; a cloud termination would disrupt operations but not destroy core IP or production
Inferred
Agent_Inference
business_model_type_secondary
Secondary R&D data management and formulation IP development; cloud migration risk is moderate and recoverable within 60–90 days
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; company relies on internal proprietary bioprocessing technology, not third-party API platforms; switching cost risk is minimal
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is product sales and licensing of plant-cell-derived ingredients, not investment contracts or token-based schemes
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; B2B ingredient sales do not involve significant consumer personal data collection; compliance burden is low
Inferred
Agent_Inference
antitrust_exposure_flag
Low antitrust risk; niche plant-cell bioactives market with no dominant market share; no horizontal merger or exclusionary conduct concerns identified
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Predominantly transactional at current stage; long-term supply agreements being pursued but recurring contract revenue is below 20% of total
Inferred
Agent_Inference
monetization_vector
B2B ingredient sales (nutraceutical and cosmetic manufacturers) plus licensing of BioFarm platform technology to strategic partners
Inferred
Agent_Inference
pricing_architecture
Cost-plus with premium for proprietary bioactive concentration; pricing stress-tested against synthetic and botanical alternatives; margin resilient if scale achieved
Inferred
Agent_Inference
pricing_power_rating
Moderate; differentiated by clinically studied bioactive profiles, but commodity botanical alternatives cap ceiling pricing power at ~2–3x conventional inputs
Inferred
Agent_Inference
target_gross_margin_bracket
Target 60–70% gross margin at scale; currently below 40% due to early-stage production costs and limited volume throughput
Inferred
Agent_Inference
churn_vulnerability_index
Low free-rider risk; proprietary bioactive ingredients are not replicable without licensed BioFarm technology; IP moat limits leakage
Inferred
Agent_Inference
headcount_cost_structure
Sublinear at scale; BioFarm bioreactor model is capital-intensive but not headcount-linear; doubling revenue does not require doubling staff
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth declines with bioreactor capacity additions; primary constraint is capex for new cultivation units, not variable labor
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC likely decreases as brand credibility grows; key risk is whether B2B pipeline can absorb volume without heavy sales force expansion
Inferred
Agent_Inference
network_effect_present
No meaningful network effects; value is derived from proprietary biology and IP, not user-base growth or platform dynamics
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk is low; core value is biological cultivation IP, not knowledge work; AI may accelerate R&D but cannot replace bioprocessing assets
Inferred
Agent_Inference
recession_resistance_tier
Moderate vulnerability; premium nutraceutical ingredients face trading-down risk in recession; cosmetic ingredient demand is more discretionary
Inferred
Agent_Inference
customer_segment_primary
Nutraceutical and dietary supplement manufacturers seeking clinically validated plant-derived bioactives
Inferred
Agent_Inference
customer_segment_secondary
Cosmetic and personal care ingredient formulators; early-stage pharmaceutical/botanical drug development partnerships
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital is being deployed forward into BioFarm bioreactor scale-up; no legacy infrastructure drag; capex is growth-oriented and future-state focused
Inferred
Agent_Inference
sec_cik
0001723464
High
SEC-EDGAR
ticker
BHST
High
SEC-EDGAR